Tocilizumab for treating severe COVID-19 pneumonia refractory to combined hydroxychloroquine, lopinavir plus ritonavir and favipiravir: case series

Autor:	Duangjai Sahassananda, Theerapat Racharak, Supat Chamnanchanunt, Manoon Surabotsophon, Suthee Leelasetakul, Wannada Laisuan, Vipa Thanachartwet, Sirote Khunapornphairote, Samlee Hapunna, Yingyot Klai-On, Somjit Jinapuk, Varunee Desakorn
Rok vydání:	2020
Předmět:	musculoskeletal diseases ARDS medicine.medical_specialty business.industry virus diseases Lopinavir Hydroxychloroquine Favipiravir medicine.disease Gastroenterology respiratory tract diseases Pneumonia chemistry.chemical_compound Tocilizumab chemistry Refractory immune system diseases Internal medicine Medicine Ritonavir skin and connective tissue diseases business medicine.drug
DOI:	10.22541/au.159527014.49016403
Popis:	Three patients with COVID-19 pneumonia received treatment with hydroxychloroquine combined with lopinavir plus ritonavir and favipiravir. Two patients early diagnosed with COVID-19 pneumonia received tocilizumab at severe pneumonia diagnosed and survived. The third patient was late diagnosed and received tocilizumab when the disease progressed to ARDS, and passed away.
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_________::b48c1b859a909efa7012f272a99e5b33 https://doi.org/10.22541/au.159527014.49016403 Zobrazit plný text záznamu